Trial reportOncotarget2017
Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.
Trial report in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03547804 (A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.The oncologist · 2019Trial
- Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.Scientific reports · 2017Trial
- Apatinib beyond first progression is associated with prolonged overall survival in patients with advanced breast cancer: Results from an observational study.Experimental and therapeutic medicine · 2024Article
- Estimating the natural indirect effect and the mediation proportion via the product method.BMC medical research methodology · 2021Article
- Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.Cancer medicine · 2020Article
- Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202).American journal of cancer research · 2020Article
- Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.Cancer management and research · 2020Article
- Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-BioMed research international · 2020Article
- Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.BMC pharmacology & toxicology · 2019Article
- Influence and mechanism of lung cavitation development on antiangiogenic therapy.Translational lung cancer research · 2019Article
- Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study.Oncology letters · 2019Article
- Observational
- Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study.OncoTargets and therapy · 2019Article
- Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma.Oncology letters · 2018Article
- New therapeutic options opened by the molecular classification of gastric cancer.World journal of gastroenterology · 2018Review
- Review
- Progress in the treatment of solid tumors with apatinib: a systematic review.OncoTargets and therapy · 2018Review
- Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib.OncoTargets and therapy · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR). PFS was the primary mediator of the association between apatinib treatment and OS, with an indirect-effect mean survival time ratio of 1.63 (95%CI 1.35-1.97), which mediated 93.5% of the treatment effect. The DCR was also a significant mediator among secondary efficacy endpoints, and had an indirect-effect mean survival time ratio of 1.47 (95%CI 1.20-1.79, 50.9% mediated). Both primary and other targets of the DCR had similar results. The results indicated that apatinib treatment prolongs progression-free survival rather than post-progression survival, and in turn, leads to improved overall survival. Additionally, our study highlights the value of mediation analysis in clinical trials in providing additional information to build upon traditional primary analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.